Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Share-based Compensation (2016 - 2025)

Mimedx (MDXG) has disclosed Share-based Compensation for 15 consecutive years, with $2.5 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 47.52% to $2.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.4 million through Dec 2025, down 3.17% year-over-year, with the annual reading at $16.4 million for FY2025, 3.17% down from the prior year.
  • Share-based Compensation hit $2.5 million in Q4 2025 for Mimedx, down from $4.9 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $4.9 million in Q3 2025 to a low of $530000.0 in Q4 2022.
  • Historically, Share-based Compensation has averaged $3.8 million across 5 years, with a median of $4.1 million in 2021.
  • Biggest five-year swings in Share-based Compensation: tumbled 82.57% in 2022 and later surged 727.55% in 2023.
  • Year by year, Share-based Compensation stood at $3.0 million in 2021, then crashed by 82.57% to $530000.0 in 2022, then soared by 727.55% to $4.4 million in 2023, then grew by 7.0% to $4.7 million in 2024, then tumbled by 47.52% to $2.5 million in 2025.
  • Business Quant data shows Share-based Compensation for MDXG at $2.5 million in Q4 2025, $4.9 million in Q3 2025, and $4.8 million in Q2 2025.